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RUNX11. Introduction
Aspirin is commonly used to prevent cardiovascular disease and
colon cancer – leading causes of death and disease worldwide. There
are large knowledge gaps in how this drug produces such diverse ef-
fects. Aspirin inhibits platelet function through platelet COX-1 suppres-
sion (Burch et al., 1978). However, this “on-target” mechanism is
insufﬁcient to explain aspirin's full effects on platelets since aspirin re-
sistance (deﬁned as aspirin's ability to inhibit platelet COX-1) is rare
(Grosser et al., 2012) and uninhibited COX-1 does not explain variation
in aspirin's effects on platelet function (Voora et al., 2012). Further, this
mechanism is not implicated in cancer (Guillem-Llobat et al., 2014). In
our prior work (Voora et al., 2013) we used aspirin as a probe in anenomics & Precision Medicine,
nited States.
geoffrey.ginsburg@duke.edu
. This is an open access article underexperimental human system and assayed aspirin's pharmacodynamic
effects using several assays of platelet function to comprehensively
identify the effects of aspirin on platelet function. In 50 healthy volun-
teers administered 325 mg/day aspirin and simultaneous peripheral
blood gene expression proﬁling before and after aspirin exposure, we
identiﬁed an aspirin response signature (ARS) as a set of 62 tightly co-
expressed genes in peripheral blood RNA that was correlative of the ef-
fects of aspirin on ADP, epinephrine, and collagen induced platelet ag-
gregation (Voora et al., 2013). We subsequently validated the ARS in
an independent cohort of 53 healthy volunteers and 132 patients with
cardiovascular disease (Voora et al., 2013). That we did not observe a
correlation between the ARS and platelet function in the absence of as-
pirin exposure suggested that part of the biologic effect of aspirin may
be to modify platelet function via changes in gene expression. Here,
we show that RUNX1, a key regulator of numerous genes governing
both platelet and megakaryocyte biology, is an aspirin-responsive tran-
scription factor and this represents an effect of aspirin on platelet/mega-
karyocyte biology and protection against cardiovascular events. RUNX1the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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we show that RUNX1 and aspirin-responsive genes regulated by RUNX1
are dysregulated in colon cancer and are associated with cancer-free
survival.
2. Materials and Methods
2.1. Megakaryocytes
Human erythroleukemia (HEL) cells (ATCC, Manassas,VA) were
grown in RPMI-1640medium (Mediatech,Flemington, NJ) supplement-
edwith 10% fetal bovine serum(HyClone, ThermoFisher Scientiﬁc, Pitts-
burgh, PA) and 1% of antibiotics (penicillin and streptomycin from
ATCC, Manassas, VA). To induce megakaryocytic transformation, HEL
cells were grown in the presence of phorbol 12-myristate 13-acetate
(10 nM PMA) for 24 h (Jalagadugula et al., 2010). Megakaryocytic HEL
cells (1 × 10^6) were treated with acetylsalicylic acid (ASA, Sigma, St.
Louis, MO) or sodium salicylic acid (SS, Thermo Fisher Scientiﬁc, Pitts-
burgh, PA) (0.1, 0.5 and 1 mM) for 24, 48 and 72 h. In control experi-
ments cells were treated with DMSO (Dimethylsulfoxide). In 48 and
72 h experiments, medium was replenished with fresh ASA or SS
every 24 h. Cells were harvested and centrifuged (at 2000 rpm for
2 min on a table top centrifuge) and the pellets were resuspended in
RNAprotect Cell Reagent (Qiagen, Venlo, Limburg) in 1:5 volume.
2.2. Description of Human Cohorts
Healthy volunteers (n = 53) were exposed to 325 mg/day aspirin
for four weeks according to a previously published experimental proto-
col (Voora et al., 2012; Voora et al., 2013). Peripheral blood for RNA
analysis and puriﬁed platelets for proteomic analyses were banked be-
fore and after aspirin exposure as previously described (Voora et al.,
2013).
Two cohorts of patients with cardiovascular disease, baseline clini-
cal, medication, and peripheral blood microarray data, and long-term
clinical outcomes from the Duke Catheterization Genetics (CATHGEN)
cohort have been previously described (Voora et al., 2013).
All human subject participants provided signed informed consent
and protocols were approved by the Duke University Institutional Re-
view Board according to standards indicated by the Declaration of
Helsinki.
2.3. RNA Puriﬁcation
RNA was isolated from HEL cells from cultured megakaryocytes
using the QIAgen miRNAeasy Mini Kit (cat.no. 217004) following the
manufacturer's QIAcube protocol and from peripheral blood as previ-
ously described (Voora et al., 2013).
2.4. qPCR
After determining sufﬁcient RNA quality and quantity, cDNA was
synthesized using SuperScript VILO Master Mix (Life Technologies;
Grand Island, NY) in 20ul reactions using 500 ng of RNA. The reactions
were run according to the manufacturer's recommended protocol. Ali-
quots of RNA samples were diluted to matching concentrations prior
to cDNA synthesis. This reaction generated cDNA at a ﬁnal estimated
concentration of 25 ng/μl. PCR was performed in 10ul triplicate wells
with 2.5 ng cDNA/well with the following kit: BioLine Lo-Rox SYBR
#BIO-94020 and the following protocol: 95° 2 min, 95° 5 s, 55° 20 s,
95° 15 s, 55° 1min. Gene expression for targets of interestwere normal-
ized to the geometric mean expression of normalizing genes (FPGS and
GAPDH) as previously described (Voora et al., 2013). Primers used in
this study are available upon request.2.5. Statistical Analysis
2.5.1. Enrichment Analyses
ChIP – seq peaks for RUNX1 were obtained from the supplemental
data of Tijssen et al. (2011). The coordinates of the peaks were convert-
ed from hg18 to hg19 using liftOver (https://genome.ucsc.edu/cgi-bin/
hgLiftOver) and gene annotation was determined using Homer
(http://homer.salk.edu/homer/ngs/index.html). Peaks that were anno-
tated as intergenic were assigned to genes with transcription start
sites (TSS) within 100 kb of the peak. HUGO gene symbols where then
used to match ChIP-seq peaks with Affymetrix gene expression probe
identiﬁers. A one-sided Fisher's exact test was used to test enrichment
of RUNX1 binding sites (ChIP-seq peaks) and predicted combinations
of transcription factors among genes in the Aspirin Response Signature
compared to all other expressed genes. The enrichment p-value was
veriﬁed though permutations testing random gene sets.2.5.2. PCR Analysis
Normalized expression data as previously described (Voora et al.,
2013). The fold change relative to vehicle control was calculated by di-
viding the expression for each time point by the average expression of
the vehicle control from that experiment and that time point. Unpaired
t-tests were used to compare fold changes in expression at each time
point vs. vehicle control.2.5.3. Platelet Proteomic Analyses
Platelet proteomic data was normalized as previously described
(Voora et al., 2013) and ﬁltered to focus on those protein products of
genes that we identiﬁed as down-regulated in a platelets of a patient
with RUNX1 haploinsufﬁciency (Sun et al., 2007).
HealthyVolunteer expression analysis –platelet function score andmi-
croarray gene expression data from health volunteers (available through
the Database of Genotypes and Phenotypes [dbGaP] phs000551.v1.p1)
before and after exposure and the aspirin response signature (ARS)
was calculated as previously described (Voora et al., 2013). Correlations
between individual probe sets, aspirin response signature (ARS), and
platelet function score were performed using Spearman correlation.2.5.4. CATHGEN RUNX1 Expression Analysis
Microarray gene expression data was normalized using RMA sepa-
rately for the two cohortsmaking up the CATHGEN study: observational
(N = 190) and case-control (N = 397) (Voora et al., 2013) available
through dbGaP (phs000551.v1.p1). In each cohort, logistic regression
was used to evaluate the effect of each RUNX1 probe expression on
myocardial infarction (MI) or death events. Two covariate models
were evaluated: 1) the reduced covariate model controlling for the ef-
fects of age on time to event, and 2) the full covariate model controlling
for the effects of age, sex, race, smoking status, hyperlipidemia, hyper-
tension, diabetes, platelet function, aspirin treatment, and the projected
aspirin response gene expression signature. RUNX1 probes were tested
for a probe-set effect onMI or death events using the score-basedGlobal
Test (Goeman et al., 2005). Two nested logistic regression models were
contrasted, the alternative model including all RUNX1 probes and co-
variates listed above and the null model including only the covariates
listed above.Meta-analysiswas used to combine evidence of RUNX1ex-
pression on survival in each cohort for both the probe-level and probe-
set analyses. For the probe-level analyses, the log odds ratios and their
standard errors were pooled as theweighted average of the log odds ra-
tios using inverse variance weights, assuming a ﬁxed effect model. For
the probe-set analysis, Fisher's method was used to combine p-values
from the cohort level Global Test results. All data processing and statis-
tical analyses were conducted in R version 3.2 (http://www.r-project.
org/) using packages affy, globaltest, and meta for normalization,
probe-set tests, and meta-analyses respectively.
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Microarray gene expression datasets (GEO accessions GSE14333
[N = 290] (Jorissen et al., 2009) and GSE17536 [N = 177] (Smith et
al., 2010)) were downloaded and each experiment normalized using
RMA. Probe-level analyses were conducted in each experiment using
the Cox proportional hazards model, modeling disease free survival
time as a function of probe expression while controlling for cancer
stage. TheARSprobe-setwas tested for an effect on disease-free survival
using the score-based approach Global Test (Goeman et al., 2005). Re-
sults from each experiment were combined using meta-analysis. The
probe-level results were pooled assuming a ﬁxed effects model using
the weighted average of the log hazards ratios with inverse variance
weights. For the probe-set analysis, Fisher's method was used to com-
bine the Global Test p-values from each experiment. All data processing
and statistical analyses were conducted in R version 3.2 (http://www.r-
project.org/) using packages affy, survival, globaltest, and meta for nor-
malization, survival analyses, probe-set tests, and meta-analyses
respectively.
Differential expression analysis was conducted in GSE14333 and
GSE17536 using amoderated t-test (Smyth, 2004) to contrast probe ex-
pression between cancer stages 1 and 2, stages 1 and 3, and stages 1 and
4. Meta-analysis was conducted using the weighted average of the log2
fold change with inverse variance weights. All statistical analyses were
conducted in R version 3.2 (http://www.r-project.org/) using packages
limma differential expression analysis and meta for meta-analyses.
3. Results
3.1. RUNX1 Regulates Aspirin Response Signature Genes
To identify potential transcription factor (s) thatmay be directly reg-
ulated by aspirin and as a consequence affect aspirin response signature
(ARS) gene expression, we used chromatin immunopreciptation se-
quencing (ChIP-seq) data (Tijssen et al., 2011) generated by using
RUNX1, GATA 1 or 2, FLI1, and SCL as probes in megakaryocytic cell
lines to identify geneswith putative binding sites for these transcription
factors. Each transcription factor had binding sites thatwere signiﬁcant-
ly (p-value ≤ 0.001) enriched in ARS gene promoters demonstrating
that each of these transcription factors – either alone or in combination
- in megakaryocytes may transcriptionally regulate ARS genes. Loss of
functionmutations in RUNX1 in humans (an autosomal dominant disor-
der named Familial Platelet Disorder with associated Myeloid Malig-
nancy (Song et al., 1999a)) lead to defects in platelet function
including agonist-induced aggregation, secretion, protein phosphoryla-
tion, and activation of GPIIb and GPIIIa, thrombocytopenia, and down
regulation in several platelet genes including ALOX12, MYL9, and PF4
(Sun et al., 2004; Song et al., 1999b; Songdej and Rao, 2015), thus pro-
viding a useful model to study human RUNX1 loss of function. In a
human subject with a truncating mutation in the RUNX1 DNA binding
RUNT domain leading to haplodeﬁciency, we identiﬁed over 200 plate-
let genes that are down-regulated (Sun et al., 2007). A majority (60%,
37/62) of ARS genes identiﬁed in our prior study (Voora et al., 2013)
are down regulated in RUNX1 haplodeﬁciency and 48% (28/62) of ARS
genes contain putative RUNX1 binding sites based on ChIP-seq data,
with several (Jalagadugula et al., 2010; Kaur et al., 2010; Aneja et al.,
2011) shown to be direct transcriptional targets of RUNX1. Therefore
a large proportion of ARS genes appear to be regulated, in part, by
RUNX1.
3.2. Aspirin Affects RUNX1 Expression in Megakaryocytic Cells
To test the hypothesis that aspirin directly regulates RUNX1 (and as a
consequence, ARS gene expression), we exposed megakaryocytic cells
to aspirin. RUNX1 expression is known to initiate at two, alternate
(Levanon and Groner, 2004) promoter start sites (P1, distal, and P2,
proximal, Supplementary Data) that produces isoforms that havenonredundant (Bee et al., 2010) roles in hematopoiesis and whose
ratio is important for megakaryocyte vs. erythrocyte differentiation
(Draper et al., 2016). We exposed megakaryocytic cell lines to aspirin
for up to 72 h and found that aspirin concentrations ≥0.5 mM down-
regulatedRUNX1P2 expression (Fig. 1A) and up regulatedRUNX1 P1 ex-
pression (Fig. 1A) with a suppression of the P2/P1 ratio (Fig. 1A). When
we tested the effects of aspirin's mainmetabolite, salicylic acid - a weak
COX-1 inhibitor - we found similar changes in RUNX1 expression as
with aspirin (Fig. 1B). Thus both aspirin and its primary metabolite
have similar effects on RUNX1 expression. To test the hypothesis that
aspirin-induced changes in RUNX1 expression alters RUNX1 function
and regulation of downstream genes, we examined ALOX12 and MYL9
- two genes that we have shown are direct transcriptional targets of
RUNX1 (Kaur et al., 2010; Jalagadugula et al., 2010) and are members
of the ARS gene set (Voora et al., 2013). We found that aspirin down-
regulated MYL9, which encodes myosin light chain, a component of
the motor protein myosin. ALOX12 expression was not decreased
(Fig. 1C), suggesting that not all RUNX1 targets genes are affected.
Overall, a pharmacodynamic effect of aspirin and its metabolite salic-
ylate are to down regulate P2 and upregulate P1 RUNX1 expression in
megakaryocytic cells and as a consequence, RUNX1 function, thus al-
tering the expression of a downstream gene known to inﬂuence
platelet function.3.3. RUNX1 Regulated Genes Are Aspirin Responsive
To test the effects of aspirin on the RUNX1 pathway in vivo, we ad-
ministered 325 mg/day non-enteric coated aspirin for four weeks to
healthy volunteers in an experimental setting where compliance was
ensured (Voora et al., 2012). Because, very lowRUNX1expression in pu-
riﬁed platelets (Ct values N 30 in over half of samples) precluded accu-
rate quantiﬁcation for comparative purposes of gene expression
analysis by PCR, we assayed for RUNX1 expression in peripheral
blood. To study RUNX1 regulated genes and proteins we analyzed puri-
ﬁed platelets before and after aspirin exposure. Similar to the response
observed in HEL cells, in peripheral blood from healthy volunteers, aspi-
rin exposure resulted in an up-regulation in RUNX1 P1 and down-regu-
lation in the P2/P1 ratio (Fig. 2A). Therefore, RUNX1 gene expression in
peripheral blood may represent a pharmacodynamic biomarker for the
gene expression modulating effects of aspirin. In puriﬁed platelets from
the same subjects, aspirin exposure was associated with higher MYL9
gene expression in platelets (Fig. 2B), indicating that aspirin alters the
expression of this gene. ALOX12 levels were not altered (Fig. 2B). We
performed open label proteomics on platelet protein (Voora et al.,
2013) and ﬁltered this dataset of 235 proteins to those 22 genes that
are differentially expressed in the patient with RUNX1 haplodeﬁciency
(Sun et al., 2007). Nearly all proteins (21/22) were responsive to aspirin
exposure, including MYL9 (Fig. 2C); the majority (19/21) were up-
regulated.3.4. RUNX1 Regulated Platelet Proteins Are Associated With Platelet
Function
To test the hypothesis that aspirin-responsive, RUNX1-regulated
proteins underlie variation in platelet function, we correlated platelet
protein expression with a composite metric (named the platelet func-
tion score (Voora et al., 2012)) of ADP, epinephrine, and collagen in-
duced platelet aggregation before and after aspirin exposure. All 21
aspirin-responsive proteins, including MYL9, were correlative of plate-
let function (Fig. 2D and Table 2) regardless of aspirin exposure. Aspirin
exposure did not change the platelet count (data not shown). The con-
sistency of effects across RUNX1-regulated proteins demonstrates that
aspirin affects the RUNX1 pathway in vivo and provide an additional
mechanism for aspirin's effects on modulating platelet function.
Fig. 1. Aspirin and salicylate effects on RUNX1 P2 and P1. Megakaryocytic HEL cells were exposed to escalating concentrations and durations of aspirin (panel a) or salicylic acid (panel b).
Changes in RUNX1 P1, P2, and the P2/P1 ratio in response to aspirin or salicylic acid are displayed relative to DMSO. Effects of aspirin on two RUNX1 regulated genes,MYL9 and ALOX12
(panel c). Data are mean ± standard error of the mean. (*) = p-values b 0.05 and (−) = p-values for ≤0.08 for unpaired parametric two-tailed t-tests of fold change of aspirin or
salicylate compared to DMSO for each time point. Each bar represents the average of 4–5 experiments.
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Fig. 2. Effects of aspirin exposure on RUNX1 function in humans. a, In peripheral blood RNA, RUNX1 P1, P2, and the P2/P1 ratio is displayed at baseline and after 4 weeks of 325 mg/day
aspirin exposure in healthy volunteers (n = 45). Data are mean ± standard error of the mean (SEM, y-axis, scaled 0.75–1.25). Panels b and c, in puriﬁed platelet RNA (B) and platelet
protein (C) from healthy volunteers exposed to 325 mg/day aspirin, MYL9 expression before and after aspirin exposure is displayed. Data are SEM (y-axis, scaled 0.75–1.25). * = p-
values b 0.05 for unpaired parametric two-tailed t-tests compared to DMSO at for each time point. Panel d, Using a previously described (Voora et al., 2013) composite metric of nine
platelet function measures termed the Platelet Function Score, MYL9 protein expression (x-axis) is plotted versus the platelet function score (y-axis) before and after aspirin exposure
in healthy volunteers. P-value represents ANOVA p-value comparing mixed-effects models with vs. without MYL9 protein expression. Shaded area represents 95% conﬁdence interval
around regression line.
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Aspirin prevents cardiovascular death and myocardial infarction
(MI). Based on our ﬁndings above in megakaryocytes and humans, we
hypothesized that this aspirin-responsive pathway is associated with
death or MI. To test this hypothesis we utilized data from two indepen-
dent cohorts (case-control and observational) of patients with cardio-
vascular disease who were treated with aspirin for which we have
previously demonstrated an association between ARS gene expression
in peripheral blood with death or MI·(Voora et al., 2013) To explore
the relation between aspirin, platelet function, and cardiovascular
events with RUNX1 gene expression we used RUNX1 probe sets that
were available on the U133 microarray and that map to the RUNX1
locus on chromosome 21 (Supplementary Data). To ensure that these
probe sets could represent RUNX1 expression and distinguish between
RUNX1 P1 vs. P2 expression we applied two criteria: 1) inclusion of
those probe sets that uniquely map to a single gene (i.e. exclusion of
probe sets with ‘s_at’ or ‘x_at’ sufﬁxes) and 2) correlation with PCR-
based RUNX1 P1 or P2 expression in healthy volunteers, respectively.
Based on these criteria four probe sets (Supplementary Data) met our
criteria and were used to represent RUNX1 P1 (233690_at and
220918_at) and P2 (1557527_at and 210365_at) expression.
To test thehypothesis that RUNX1probe set expressionwas correlat-
edwith either ARS gene expression or platelet functionwe used healthy
volunteer data before and after aspirin exposure (Voora et al., 2013).
The RUNX1 P2 probe set 210365_at was associated with ARS expression
at baseline and after aspirin exposure; neither P2 probe set was associ-
ated with platelet function (Table 1). In contrast, P1 probe set
220918_at was associated with ARS gene expression and platelet func-
tion after aspirin exposure. Therefore, peripheral blood RUNX1microar-
ray data are consistent with the hypothesis that the P1 RUNX1 isoform
regulates ARS gene expression and platelet function in an aspirin de-
pendentmanner. To test the hypothesis that RUNX1 expressionwas as-
sociated with cardiovascular events we again focused on these four
probe sets (Fig. 3A). The RUNX1 P2 probe sets were not associated
with death orMI, however, both P1 probe setswere consistently protec-
tive for death orMI (Fig. 3A). This ﬁnding extends the pharmacologic ef-
fect of aspirin on upregulating RUNX1 P1 expression to the antiplatelet
effects of aspirin on platelet function and cardiovascular events.
3.6. Aspirin Response Signature Genes Are Associated With Colorectal Can-
cer Stage and Survival
Beyond its use in cardiovascular disease, aspirin use is recommend-
ed to prevent GI malignancies (Bibbins-Domingo, 2016) and is being
tested (NCT02467582, NCT02301286, and NCT00565708) as adjuvant
therapy in patients treated for colon cancer. RUNX1 is a known tumorTable 1
Correlation of RUNX1 probe sets with Aspirin Response Signature expression and platelet
function before and after aspirin exposure in healthy volunteers.
Probe set
ID
Correlation coefﬁcients
Pre-aspirin
ARS
Post-aspirin
ARS
Change in
ARS
(post-pre)
Pre-aspirin
platelet
function
score
Post-aspirin
platelet
function
scorea
P2 RUNX1 probe sets
210365_at 0.31⁎ 0.39⁎⁎ 0.30⁎⁎ −0.01 −0.07
1557527_at −0.12 −0.12 −0.01 0.16 0.15
P1 RUNX1 probe sets
233690_at −0.11 −0.05 0.13 −0.15 0.10
220918_at −0.18 −0.45⁎⁎ −0.27⁎ −0.03 0.34⁎⁎
⁎ p ≤ 0.05.
⁎⁎ p ≤ 0.01.
a The platelet function score (11) (PFS) was used to quantify platelet function before
and after aspirin exposure.suppressor gene in acute myeloid leukemia (AML (Ichikawa et al.,
2013)) and gastrointestinal (GI) malignancies (Fijneman et al., 2012;
Dulak et al., 2012). RUNX1 (Sakakura et al., 2005) and several ARS
genes (MYL9 (Yan et al., 2012), CTTN (Gardina et al., 2006), CALD1
(Gardina et al., 2006), SPARC (Chew et al., 2011)) are dysregulated in
GI malignancies. To test the hypothesis that RUNX1 and its downstream
ARS genes represent a mechanistic link for the chemoprotective effects
of aspirin on GI cancers, we tested the association of the microarray ex-
pression of RUNX1 and ARS genes with colorectal cancer stage and can-
cer free survival in two independent cohorts (Smith et al., 2010; Jorissen
et al., 2009) not previously studied for these genes. We found that
RUNX1 and the majority of ARS probe sets are expressed in normal
colon tissue (53/72) as well as in colon cancer samples (68/72). To
test the hypothesis that aspirin responsive RUNX1was associated with
disease-free survival, we tested the P2 and P1 RUNX1 probe sets and
found that higher expression of RUNX1 P1 probe sets were associated
with survival (meta-analysis hazard ratio for P1 probe sets 233690_at
and 220918_at, 95% conﬁdence intervals, and meta-analysis p-values
were 1.6 [1.1 – 2.3], 0.01 and 1.6 [0.9 – 2.7], 0.09, respectively). The re-
maining RUNX1 probe sets were not associated with survival or with
cancer stage (data not shown). Further, the RUNX1 responsive, ARS
gene set was differentially expressed in advanced colon cancer stage
(B-D) compared to stage A cancers (genesettest p-values =
1.34e−06 and 0.001). In particular, several ARS genes includingMYL9,
were up-regulated in stages B–D compared to stage A (Fig. 3B, Supple-
mentary Data). Furthermore, independent of cancer stage, several ARS
genes including SPARC, CTTN, CALD1, andMYL9 in colorectal cancer tu-
mors were associated with cancer-free survival (meta-analysis odds ra-
tios = 1.3–2.7, meta-analysis p-values b 0.01, Supplementary Data). To
account for potential confounding by clinical characteristics and treat-
ments, we included age, sex, adjuvant chemotherapy, and adjuvant ra-
diation therapy as covariates in the Jorissen et al. analysis. Aspirin use
was not available in either. To test for potential confounding effects,
we compared effect sizes for each ARS and RUNX1 probeset in the sur-
vival analysis with and without inclusion of these covariates and
found a strong correlation of effect sizes (r=0.94, slope=1.02, Supple-
mentary Data). These data suggest that the aspirin responsive RUNX1 –
ARS pathway that we identiﬁed in blood may be active in colon cancers
and illuminates a potential additional mechanism for aspirin's
chemoprotective role following colon cancer diagnosis.
4. Discussion
Aspirin is widely used to prevent cardiovascular disease and is rec-
ommended (Bibbins-Domingo, 2016) to prevent colon cancer. To
study the effects of aspirin, we used a systems pharmacogenomics ap-
proach that combines systems biology, genetics, and pharmacology.
Previously, we used serial gene expression proﬁling in humans exposed
to aspirin (Voora et al., 2013). We identiﬁed an aspirin response signa-
ture (ARS) as a set of peripheral blood genes, that correlatedwith the ef-
fects of aspirin on platelet function, suggesting that part of the biologic
effect of aspirin on platelet function may be to modify platelet gene ex-
pression (Voora et al., 2013). Because of the co-expressed nature of the
ARS and their platelet origin we tested the hypothesis that aspirin pro-
duces its effects on gene expression through modulation of a megakar-
yocytic transcription factor (s). Our ﬁndings demonstrate that 1) ARS
genes are RUNX1 responsive 2) aspirin and salicylate directly regulate
RUNX1 in a promoter speciﬁc (P1 versus P2) fashion; 3) aspirin inﬂu-
ences ARS gene expression in megakaryocytes and platelets; 4) RUNX1
P1 gene expression is associated with improved long-term clinical out-
comes in patientswith cardiovascular disease and colon cancer. Togeth-
er, these ﬁndings provide evidence for an effect for aspirin on RUNX1
gene expression and function. This aspirin-responsivemechanism is im-
plicated in cardiovascular disease and colon cancer outcomes.
It iswell known that aspirin'smechanismof action is to inhibit plate-
let COX-1. However, aspirin likely has additional mechanisms for
Fig. 3. RUNX1 and MYL9 association with cardiovascular events or colon cancer stage Panel a, Using whole blood RNA microarray data collected from patients at the time of cardiac
catheterization and long-term follow up for death and myocardial infarction (MI), we assembled case-control (n = 190) and observational patient cohorts (n = 397) where we have
previously shown (Voora et al., 2013) an association between an Aspirin Response Signature (ARS) and death/MI events. The associations of P2 and P1 RUNX1 probe sets (see text for
deﬁnitions) with death or MI in the observational and case-control individually and combined through meta-analysis are displayed as log Odds Ratios and 95% conﬁdence intervals.
Log odds ratios less than zero correspond to protective effects (i.e. higher expression associated with lower risk) and vice versa. All analyses are adjusted for age and sex. Panel b,
Normalized expression for RUNX1 P1 probe sets are plotted vs. death or MI outcomes in the combined observational and case-control cohorts. Panel c, using two publically available
datasets of colorectal cancer tumors (Jorissen et al. (2009), n = 290 and Smith et al. (2010), n = 177), a meta-analysis of differential MYL9 expression for stages B–D vs. A was
conducted and the log2 fold change and 95% conﬁdence intervals for each pairwise comparison is presented.
162 D. Voora et al. / EBioMedicine 11 (2016) 157–164inhibiting platelet function because aspirin doses in excess of 81mg/day
do not result in additional COX-1 suppression but produce additional
platelet inhibition as assessed by ADP and collagen (Gurbel et al.,Table 2
Correlation with platelet function and change in response to aspirin exposure for RUNX1
regulated platelet proteins.
Protein
symbol
Regression coefﬁcient for
correlation with platelet
function
Regression
p-value
Mean
difference
(pre-post)
Paired t
test
p-value
FLNA 0.11 0.01 3.91 0.01
F13A 0.20 0.01 1.83 0.02
PDE5A −0.35 0.34 −0.06 0.78
SH3L2 −1.31 0.01 −0.26 0.03
ILEU −1.10 0.02 −0.28 0.03
PGH1 −1.36 0.00 −0.30 0.03
VDAC3 −1.11 0.02 −0.33 0.01
JAM1 −0.84 0.03 −0.36 0.02
1433F −1.04 0.01 −0.39 0.02
NP1L1 −0.70 0.02 −0.46 0.02
CALD1 −0.65 0.01 −0.69 0.02
PRDX6 −0.55 0.01 −0.70 0.02
LEGL −0.58 0.01 −0.72 0.01
TBA4A −0.48 0.01 −0.80 0.01
SDPR −0.44 0.01 −0.84 0.01
LTBP1 −0.48 0.01 −0.85 0.01
MYL9 −0.45 0.01 −0.89 0.01
TAGL2 −0.32 0.01 −0.99 0.06
PLF4 −0.33 0.03 −1.05 0.01
TPM4 −0.28 0.01 −1.40 0.01
TBB1 −0.28 0.01 −1.58 0.01
ACTN1 −0.20 0.01 −2.22 0.012007). Although aspirin and salicylate, are well-known to inhibit NFKB
(Kopp and Ghosh, 1994; Frantz et al., 1995), IkB phosphorylation
(Pierce et al., 1996), and other cellular kinases (Stevenson et al., 1999;
Schwenger et al., 1997), many of these effects are observed at concen-
trations not achieved (Roberts et al., 1984) with cardioprotective dos-
ages (≤325 mg/day). In support of our hypothesis that aspirin alters
gene expression,Massimi et al. identiﬁed that aspirin can upregulate ex-
pression of a single gene,MRP4, inmegakaryocytes and platelets – an ef-
fect that was attributed to variation in platelet function in response to
aspirin (Massimi et al., 2014). In this study we link the effects of aspirin
and salicylate to RUNX1, a well-known transcription factor critical for
normal hematopoiesis, megakaryocyte differentiation, and platelet
function and a number of genes that it regulates (Elagib et al., 2003).
That we observed similar effects with salicylate compared to aspirin
on megakaryocyte gene expression suggests that aspirin's ability to in-
hibit COX-1 may not be required for this effect because salicylate has a
~20-fold lower potency for inhibiting COX-1 (Riendeau et al., 1997).
Therefore in addition to the well-known effects of aspirin on platelet
COX-1, our ﬁndings identify an effect of aspirin (or its metabolite salic-
ylate) on RUNX1 and downstream gene expression.
RUNX1 is critical for normal hematopoiesis and megakaryocyte dif-
ferentiation. Deletion of RUNX1 leads to embryonic lethality in mice
due to hemorrhage (Wang et al., 1996), and humans with mutations
leading to RUNX1 haploinsufﬁciency (Song et al., 1999a) are character-
ized by thrombocytopenia, defects in multiple aspects of platelet func-
tion, and a predisposition to leukemia (Sun et al., 2004; Song et al.,
1999b; Ho et al., 1996). These prior studies in humans demonstrate
that reductions in RUNX1 expression can lead to profound changes in
platelet function. Our data demonstrate that aspirin can produce ~2
163D. Voora et al. / EBioMedicine 11 (2016) 157–164fold changes in RUNX1 in the megakaryocyte and inMYL9 - a gene that
we have shown is directly regulated by RUNX1 (Jalagadugula et al.,
2010). MYL9 plays a major role in platelet function and formation
(Gilles et al., 2009) and in megakaryocyte biology (Jalagadugula et al.,
2010). Therefore the observed effects of aspirin on RUNX1 and down-
streamgene expression provides an additionalmechanismbywhich as-
pirin modulates platelet function and prevents cardiovascular disease.
Colorectal cancer is among the most common malignancy in the US
and developed countries. Despite several lines of evidence implicating
COX-2 (Algra and Rothwell, 2012; Rothwell et al., 2010; Rothwell et
al., 2011; Clevers, 2006; Rothwell et al., 2012; Bertagnolli et al., 2006;
Arber et al., 2006) as the mechanism by which aspirin prevents colon
cancer, low-dose (b 100 mg/day) aspirin, which is associated with a re-
duced risk of colon cancer (Cook et al., 2013; Chan et al., 2008), is aweak
COX-2 inhibitor (Mitchell et al., 1993). Therefore additional mecha-
nisms linking aspirin to colon cancer prevention are likely. Our ﬁndings
demonstrate that RUNX1 and several ARS genes, which are RUNX1-re-
sponsive, are correlated with disease free survival in two independent
datasets of colon cancer patients. Therefore, ARS genes, which we
have shown are aspirin- and RUNX1-responsive in the hematopoietic
system, are also associated with colon cancer outcomes.
There are some limitations to our ﬁndings that deserve consider-
ation. First, in megakaryocytic cells, we observed a down regulation in
MYL9 compared to an upregulation in human platelets. The different di-
rections of change in MYL9 expression may be attributed to 1) differ-
ences in duration of aspirin exposure (72 h [in vitro] vs. 4 weeks [in
vivo]); the longer duration may permit compensatory mechanisms to
develop; 2) the impact of cell speciﬁc transcriptional regulators (HEL-
derived early stage megakaryocytic cells vs. native megakaryocytes),
or 3) MYL9 measured in megakaryocytic cells vs. platelets. Second,
while aspirin changed MYL9 expression there was no change in
ALOX12. One explanation is that blocking COX-1 with aspirin may
shunt arachidonic acid into the lipoxygenase pathways and thus cause
a compensatory increase in ALOX12 that balances any effects of aspirin
on RUNX1. Third, the dose- and time-dependent effects of aspirin or sa-
licylate were not linear (Fig. 1). These non-linearities will likely be un-
derstood as part of future research around the mechanism of aspirin
on RUNX1 expression. Fourth, the salicylate concentrations in this
study may be higher than those achieved clinically. Because aspirin is
quickly metabolized to salicylate, there is no systemic accumulation of
aspirin. However, there is signiﬁcant accumulation of salicylate (which
has a half-life of 3–4 h) in the 30–100 μM range (Nagelschmitz et al.,
2014; Charman et al., 1993) for 75–100 mg aspirin and 400–800 μM
(Crome et al., 1991; Nagelschmitz et al., 2014) with 300mg aspirin dos-
ing based on area under the concentration-time curve analyses. These
data, combined with the ﬁnding that we see similar effects of aspirin
on RUNX1 with 325 mg/day dosing suggests that the concentrations
used are physiologic. Last, we used an aspirin dose that is at the upper
limit of the dosage range for cardiovascular prevention (75–325 mg/
day). We chose this dose because 325 mg/day remains dosage com-
monly used in clinical practice (Hall et al., 2014) and one that is current-
ly being tested in randomized clinical trials in cardiovascular disease
(theaspirinstudy.org - NCT02697916) and colon cancer (www.capp3.
org - NCT02497820). We recognize the importance of understanding
the dose-response relationship between aspirin and RUNX1. Future
studies will examine the extent to which changes in gene expression
seen in this study extend to lower aspirin doses. Despite these limita-
tions, we show that RUNX1 is an aspirin responsive transcription factor,
leading to alteration in numerous downstream platelet genes and pro-
teins that regulate platelet function and whose levels are correlated
with known platelet physiology.
Ourwork on aspirin represents a proof-of-concept application of the
systems pharmacogenomics approach to identify novel effects for aspi-
rin that were not predicted based on aspirin's known mechanism of
COX-1 inhibition. Future work focused on identifying the mechanism
underlying this effect may lead to novel molecules that exploit thisproperty for cardiovascular disease and cancer prevention. RUNX1path-
way biomarkers may be useful to individualize and optimize antiplate-
let therapy or identify novel conditions that may be treated by aspirin.
By using a systems pharmacogenomics approachwe identify an off-tar-
get mechanism of action for one of the most commonly used medica-
tions worldwide and implicate this mechanism to cardiovascular
disease and colorectal cancer.
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